Literature DB >> 26314634

14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

H Ding1, R Underwood1, N Lavalley1, T A Yacoubian2.   

Abstract

14-3-3s are a highly conserved protein family that plays important roles in cell survival and interact with several proteins implicated in Parkinson's disease (PD). Disruption of 14-3-3 expression and function has been implicated in the pathogenesis of PD. We have previously shown that increasing the expression level of 14-3-3θ is protective against rotenone and 1-methyl-4-phenylpyridinium (MPP(+)) in cultured cells. Here, we extend our studies to examine the effects of 14-3-3s in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. We first investigated whether targeted nigral 14-3-3θ overexpression mediated by adeno-associated virus offers neuroprotection against MPTP-induced toxicity. 14-3-3θ overexpression using this approach did not reduce MPTP-induced dopaminergic cell loss in the substantia nigra nor the depletion of dopamine (DA) and its metabolites in the striatum at three weeks after MPTP administration. However, 14-3-3θ-overexpressing mice showed a later partial recovery in striatal DA metabolites at eight weeks after MPTP administration compared to controls, suggesting that 14-3-3θ overexpression may help in the functional recovery of those dopaminergic neurons that survive. Conversely, we investigated whether disrupting 14-3-3 function in transgenic mice expressing the pan 14-3-3 inhibitor difopein exacerbates MPTP-induced toxicity. We found that difopein expression promoted dopaminergic cell loss in response to MPTP treatment. Together, these findings suggest that 14-3-3θ overexpression promotes recovery of DA metabolites whereas 14-3-3 inhibition exacerbates neuron loss in the MPTP mouse model of PD.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  14-3-3s; MPTP; Parkinson’s disease; adeno-associated virus; dopamine; neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 26314634      PMCID: PMC4594956          DOI: 10.1016/j.neuroscience.2015.08.042

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  47 in total

1.  Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins.

Authors:  C Itagaki; T Isobe; M Taoka; T Natsume; N Nomura; T Horigome; S Omata; H Ichinose; T Nagatsu; L A Greene; T Ichimura
Journal:  Biochemistry       Date:  1999-11-23       Impact factor: 3.162

2.  14-3-3 proteins mediate an essential anti-apoptotic signal.

Authors:  S C Masters; H Fu
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

3.  Monomeric 14-3-3 protein is sufficient to modulate the activity of the Drosophila slowpoke calcium-dependent potassium channel.

Authors:  Yi Zhou; Smitha Reddy; Heather Murrey; Hong Fei; Irwin B Levitan
Journal:  J Biol Chem       Date:  2003-01-15       Impact factor: 5.157

4.  Specification of 14-3-3 proteins in Lewy bodies.

Authors:  Daniela Berg; Olaf Riess; Antje Bornemann
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

5.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms.

Authors:  Yanli Zhang; Michael James; Frank A Middleton; Richard L Davis
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-08-05       Impact factor: 3.568

6.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  M Vila; V Jackson-Lewis; S Vukosavic; R Djaldetti; G Liberatore; D Offen; S J Korsmeyer; S Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

7.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.

Authors:  A T Ferguson; E Evron; C B Umbricht; T K Pandita; T A Chan; H Hermeking; J R Marks; A R Lambers; P A Futreal; M R Stampfer; S Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

8.  14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains.

Authors:  Yasuhiro Kawamoto; Ichiro Akiguchi; Shinichi Nakamura; Yasuyuki Honjyo; Hiroshi Shibasaki; Herbert Budka
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

9.  Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

Authors:  Belinda S Parker; Suzanne M Cutts; Abraham Nudelman; Ada Rephaeli; Don R Phillips; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2003 May-Jun       Impact factor: 4.742

10.  14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome.

Authors:  Kazuhito Toyo-oka; Aki Shionoya; Michael J Gambello; Carlos Cardoso; Richard Leventer; Heather L Ward; Ramses Ayala; Li-Huei Tsai; William Dobyns; David Ledbetter; Shinji Hirotsune; Anthony Wynshaw-Boris
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

View more
  12 in total

1.  14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.

Authors:  Bing Wang; Rachel Underwood; Anjali Kamath; Colleen Britain; Michael B McFerrin; Pamela J McLean; Laura A Volpicelli-Daley; Robert H Whitaker; William J Placzek; Katelyn Becker; Jiyan Ma; Talene A Yacoubian
Journal:  J Neurosci       Date:  2018-08-09       Impact factor: 6.167

2.  Downregulation of 14-3-3 Proteins in Alzheimer's Disease.

Authors:  Qiang Gu; Elvis Cuevas; James Raymick; Jyotshna Kanungo; Sumit Sarkar
Journal:  Mol Neurobiol       Date:  2019-09-05       Impact factor: 5.590

3.  14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models.

Authors:  Mary Gannon; Bing Wang; Sara Anne Stringfellow; Stephan Quintin; Itzel Mendoza; Thanushri Srikantha; A Claire Roberts; Takashi Saito; Takaomi C Saido; Erik D Roberson; Talene A Yacoubian
Journal:  eNeuro       Date:  2022-06-24

4.  14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Authors:  Nicholas J Lavalley; Sunny R Slone; Huiping Ding; Andrew B West; Talene A Yacoubian
Journal:  Hum Mol Genet       Date:  2015-11-05       Impact factor: 6.150

Review 5.  14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.

Authors:  F Sanders Pair; Talene A Yacoubian
Journal:  Trends Pharmacol Sci       Date:  2021-01-28       Impact factor: 14.819

6.  Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology.

Authors:  Michael B McFerrin; Xiaofei Chi; Gary Cutter; Talene A Yacoubian
Journal:  Ann Clin Transl Neurol       Date:  2017-06-07       Impact factor: 4.511

7.  Protein-protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease.

Authors:  Yimin Mao; Daniel W Fisher; Shuxing Yang; Rachel M Keszycki; Hongxin Dong
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240

8.  14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.

Authors:  Rachel Underwood; Mary Gannon; Aneesh Pathak; Navya Kapa; Sidhanth Chandra; Alyssa Klop; Talene A Yacoubian
Journal:  Acta Neuropathol Commun       Date:  2021-01-07       Impact factor: 7.801

9.  Schisandrol A Attenuates Myocardial Ischemia/Reperfusion-Induced Myocardial Apoptosis through Upregulation of 14-3-3θ.

Authors:  Shuaishuai Gong; Jincheng Liu; Shiyao Wan; Weiwei Yang; Yuanyuan Zhang; Boyang Yu; Fang Li; Junping Kou
Journal:  Oxid Med Cell Longev       Date:  2021-06-26       Impact factor: 6.543

Review 10.  Emerging roles of 14-3-3γ in the brain disorder.

Authors:  Eunsil Cho; Jae-Yong Park
Journal:  BMB Rep       Date:  2020-11       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.